cis-2,3 dihydro tetrabenazine-D6

Cis-2,3 dihydro tetrabenazine-D6 is a deuterium-labeled isotopic form of cis-2,3 dihydro tetrabenazine, a medication that is used to treat hyperkinetic disorders such as Huntington’s disease, Tourette’s syndrome, and tardive dyskinesia. Tetrabenazine works by regulating the levels of dopamine, a neurotransmitter that is responsible for controlling movement and emotion in the brain. It acts as a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2), which is responsible for the uptake of dopamine into vesicles in nerve terminals. By inhibiting this transporter, tetrabenazine decreases the amount of dopamine available for release, thereby reducing the symptoms of hyperkinetic disorders. Cis-2,3 dihydro tetrabenazine-D6 is a stable isotope-labeled compound that is used in pharmacokinetic and pharmacodynamic studies to investigate the metabolism, distribution, and elimination of tetrabenazine in the body. It is often used as an internal standard in mass spectrometry assays to accurately quantify the levels of tetrabenazine and its metabolites in biological samples. The deuterium label in cis-2,3 dihydro tetrabenazine-D6 allows for precise measurement of drug levels and pharmacokinetic parameters, which is particularly useful in clinical trials and drug development studies. In summary, cis-2,3 dihydro tetrabenazine-D6 is a valuable tool for studying the pharmacology of tetrabenazine and improving the treatment of hyperkinetic disorders. Its chemical properties and stable isotope labeling make it an important compound in drug development and clinical research.